Lyvgen Overview
- Year Founded
-
2016
- Status
-
Private
- Latest Deal Type
-
2ndary - Private
- Investors
-
8
Lyvgen General Information
Description
Developer of immunotherapy candidates designed to treat cancer patients. The company utilises a functional platform to create agonist antibodies with tumour-localised immunostimulatory activities by balancing multiple functions of candidate antibodies, providing oncology therapeutics to improve patient outcomes through tumour-targeted immune activation.
Contact Information
Website
www.lyvgen.cnCorporate Office
- Suite 317, Building 1
- 351 Guoshoujing Road
- Shanghai
- China
Corporate Office
- Suite 317, Building 1
- 351 Guoshoujing Road
- Shanghai
- China
Lyvgen Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Secondary Transaction - Private | 30-Jul-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series C) | 23-Feb-2021 | Completed | Generating Revenue | |||
| 3. Early Stage VC (Series B1) | 01-Dec-2019 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 01-Jun-2018 | $30M | $35M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Jan-2017 | $5M | $5M | Completed | Generating Revenue |
Lyvgen Patents
Lyvgen Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10913797-B2 | Anti-pd-1 antibodies and therapeutic uses thereof | Active | 18-Nov-2015 | ||
| US-20180346569-A1 | Anti-pd-1 antibodies and therapeutic uses thereof | Active | 18-Nov-2015 |
Lyvgen Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 120 Capital | Venture Capital | Minority | ||
| Chengwei Capital | Venture Capital | Minority | ||
| IDG Capital | Venture Capital | Minority | ||
| Shanghai Free Trade Zone Equity Fund | Venture Capital | Minority | ||
| Shenzhen GTJA Investment Group | Venture Capital | Minority |
Lyvgen FAQs
-
When was Lyvgen founded?
Lyvgen was founded in 2016.
-
Where is Lyvgen headquartered?
Lyvgen is headquartered in Shanghai, China.
-
What industry is Lyvgen in?
Lyvgen’s primary industry is Drug Discovery.
-
Is Lyvgen a private or public company?
Lyvgen is a Private company.
-
What is Lyvgen’s current revenue?
The current revenue for Lyvgen is .
-
How much funding has Lyvgen raised over time?
Lyvgen has raised $75M.
-
Who are Lyvgen’s investors?
120 Capital, Chengwei Capital, IDG Capital, Shanghai Free Trade Zone Equity Fund, and Shenzhen GTJA Investment Group are 5 of 8 investors who have invested in Lyvgen.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process